Anatomic Gift Foundation Inc

What it reported doing in 2024

Major accomplishment in 2024: a. Agf maintained its accreditation by the american association of tissue banks (aatb) as a non-transplant donation organization upon passing our on-site every three-year cycle accreditation inspection; with a level a designation again in 2024. B. Agf senior staff-members have donated their time as member participants in various organizations and projects in the furtherance non-transplant anatomic donation (nado) and medical education communities; including but not limited to; aatb: nado council, education committee, membership committee, educational webinar presenter - most importantly election to the board of governors of aatb in 2022 (which continued in 2024), association for bioskills laboratory excellence (able): board member, guidance document committee, membership committee. C. All staff who were due to submit their certified tissue bank specialist (ctbs) continuing education units (ceu)s to re-certify with aatb in year 2023 have done so and have kept their certification. D. Agf maintained its New York license as a non-transplant anatomic bank. E. Agf maintained its licenses & permits by the Maryland board of morticians for operating a crematory; as well as for mortuary transporters f. Agf passed all safety and environmental inspections by various entities, i.e., fire marshall, Maryland department of environment (both air & radiation), etc. G. Agf has continued its quality systems; which include regular auditing and reporting of findings. Ii. 2024 statistics: a. Donors 1. There was a total of 1931 donors in 2024 (representing an overall 5% increase from that in 2023). Agf continued its coverage area to its home state of Maryland; and then regional states, and gradually added pre- registered donors from states out of area. The breakdown of donors by area was: md 34% (2% decrease over 2023), regional 51% (7% increase over 2023) and out-of-area 15% (5% decrease over 2023). Many potential donors who had either contracted covid-19, had symptoms without a negative test, or had direct contact with someone infected with covid-19 were not accepted; regardless of geographic area. 2. Each donor is evaluated based on a myriad of items to make an individualized tissue recovery plan to maximize the educational, research, and training endeavors made possible by their gifts. Considerations are made as to age, sex, surgical hx, pathology, bone & joint quality, etc., as well as any requests from the donor before their death or from their next of kin as to preference for placement to any disease or type of surgery or specific use). B. Future donors: -in 2024 we continued to accept applications to be pre- registered with agf to be future donors. This information is reviewed, cataloged and entered into our database for future retrieval, to assist the families at the time of death. Donor and family services coordinator staff contact our registered future donors every few years to update their medical records and next-of-kin contact information. 1. There were a total of 800 new registered (future) donors in 2024. 2. Total registered donors at the end of 2024 topped 17,000. 3. Referral sources in 2024, were: a. Online searches b. Family or friends that have dontated through agr c. Hospice end-of-life care agencies d. Hospital social workers and/or chaplains e. Funeral homes, cremation services f. State anatomy boards g. Transplant agencies (organ, tissue and/or eye) c. Tissue placement & use: a total of 7,693 specimens were placed to approved human tissue applicants in 2024; fulfilling 2,027 (an 11% increase from 2023) client requests for tissue in both our in-house bioskills lab use; or as shipments to clients' facilities (which is the predominance of placements). 1. In-house specimen use: we accommodated 64 (a 3% decrease from 2023) on- site "bioskills lab events in 2024, serving hundreds of learners. 2. A total of 196 (a 13% decrease over 2023) specimens were used on site with our in-house bioskills lab facilit

Financial Efficiency

• Mission deployment rate: 87.6%; rating input score 88
• Program expense ratio: 90.4%; rating input score 90
• Fundraising efficiency: Limited

Transparency & Controls

• Consistency checks: 100%; rating input score 100; 63rd percentile among comparable filings
• Pay-setting controls: 0 of 6 controls in place; rating input score 0
  • Compensation committee: Missing
  • Independent consultant: Missing
  • Other Form 990s reviewed: Missing
  • Written employment contract: Missing
  • Compensation survey or study: Missing
  • Board or committee approval: Missing
• Foreign activity oversight: Limited
• Grant itemization coverage: Limited
• Major donor itemization: Limited
• Related-party transparency: Limited

Accountability

• Independent voting board: 0%; rating input score 0; 3rd percentile among comparable filings
• Governance controls: 2 of 9 controls in place; rating input score 22
  • Conflict-of-interest policy: Fail
  • Whistleblower policy: Fail
  • Document-retention policy: Fail
  • CEO compensation review process: Fail
  • Other executive compensation review process: Fail
  • Form 990 shared with the board: Pass
  • Board meeting minutes documented: Pass
  • Audit committee oversight: Missing
  • Independent financial-statement audit: Fail

Sustainability

• Operating margin: 3.1%; rating input score 45; 45th percentile among comparable filings
• Total-asset coverage ratio: 0.55; rating input score 20; 20th percentile among comparable filings
• Liabilities to assets ratio: 0; rating input score 97; 97th percentile among comparable filings
• Officer compensation ratio: 9.2%; rating input score 33; 33rd percentile among comparable filings

Growth

• Program expense growth: 9.1% per year; rating input score 100; 60th percentile among comparable filings
• Revenue growth: 7.6% per year; rating input score 100; 58th percentile among comparable filings
• Asset growth: 13.1% per year; rating input score 100; 69th percentile among comparable filings